Document is current
Any future updates will be listed below
-
Authors
Sablin, Marie-Paule
Gestraud, Pierre https://orcid.org/0000-0002-3893-9879
Jonas, Sarah Flora
Lamy, Constance
Lacroix-Triki, Magali https://orcid.org/0000-0002-6641-8536
Bachelot, Thomas https://orcid.org/0000-0002-0866-9484
Filleron, Thomas
Lacroix, Ludovic https://orcid.org/0000-0003-2535-1010
Tran-Dien, Alicia
Jézéquel, Pascal
Mauduit, Marjorie
Barros Monteiro, Janice
Jimenez, Marta https://orcid.org/0000-0002-4233-8478
Michiels, Stefan https://orcid.org/0000-0002-6963-2968
Attignon, Valery
Soubeyran, Isabelle
Driouch, Keltouma
Servant, Nicolas
Le Tourneau, Christophe https://orcid.org/0000-0001-9772-4686
Kamal, Maud https://orcid.org/0000-0003-1466-0950
André, Fabrice https://orcid.org/0000-0001-5795-8357
Bièche, Ivan
-
Funding
Funding for this research was provided by:
Breast Cancer Research Foundation
Agence Nationale de la Recherche (ANR-17-RHUS-0008)
Agence Nationale de la Recherche (ANR-17-RHUS-0008)
Agence Nationale de la Recherche (ANR-17-RHUS-0008)
Fondation ARC pour la Recherche sur le Cancer
- License Information
-
More Information
Article History
Received: 21 February 2024
Revised: 17 July 2024
Accepted: 22 July 2024
First Online: 2 August 2024
Competing interests
: FA received research funding and served as speaker/advisor (compensated to the hospital) for Roche, AstraZeneca, Daiichi Sankyo, Pfizer, Novartis and Lilly. TB received research funding and served as speaker/advisor (compensated to the hospital) for Roche, Novartis, Pfizer, Seattle Genetic, Lilly and AstraZeneca. TF received research funding and served as speaker/advisor (compensated to the hospital) for Roche, Janssen, and Lilly. SM received Personal fees for DSMB or scientific committee study membership for Kedrion, Sensorion, Biophytis, Servier, Yuhan, Roche, outside the scope of the submitted work. CLT received research funding and served as speaker/advisor (compensated to the hospital) for Roche, Seattle Genetics, Rakuten, Nanobiotix, MSD, BMS, Merck Serono, AstraZeneca, GlaxoSmithKline, Novartis, Celgene, Exscientia, ALX Oncology and Seattle Genetics. The following authors have no disclosures: MPS, PG, SFJ, CL, MLT, LL, ATD, PJ, MM, MJ, VA, IS, KD, NS, MK and IB.
: SAFIR02-BREAST prospective trial was approved by the ethics committees at all participating centres. Written informed consent was obtained from all patients. The study was performed in accordance with the Declaration of Helsinki.
